CorMedix Inc [CRMD] stock is trading at $10.56, down -0.75%. An important factor to consider is whether the stock is rising or falling in short-term value. The CRMD shares have gain 7.65% over the last week, with a monthly amount drifted -5.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CorMedix Inc [NASDAQ: CRMD] stock has seen the most recent analyst activity on October 20, 2025, when D. Boral Capital upgraded its rating to a Buy but kept the price target unchanged to $14 for it. Previously, H.C. Wainwright started tracking the stock with Buy rating on June 30, 2025, and set its price target to $20. On June 30, 2025, downgrade downgraded it’s rating to Hold. Leerink Partners started tracking the stock assigning an Outperform rating and suggested a price target of $18 on March 07, 2025. D. Boral Capital initiated its recommendation with a Buy and recommended $15 as its price target on January 13, 2025. Rodman & Renshaw started tracking with a Buy rating for this stock on August 26, 2024, and assigned it a price target of $13. In a note dated August 10, 2023, RBC Capital Mkts initiated an Outperform rating and provided a target price of $6 on this stock.
CorMedix Inc [CRMD] stock has fluctuated between $5.60 and $17.43 over the past year. Currently, Wall Street analysts expect the stock to reach $19.5 within the next 12 months. CorMedix Inc [NASDAQ: CRMD] shares were valued at $10.56 at the most recent close of the market. An investor can expect a potential return of 84.66% based on the average CRMD price forecast.
Analyzing the CRMD fundamentals
CorMedix Inc [NASDAQ:CRMD] reported sales of 214.30M for the trailing twelve months, which represents a growth of 810.22%. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.49%, Pretax Profit Margin comes in at 0.5%, and Net Profit Margin reading is 1.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 1.16 and Total Capital is 0.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.37 points at the first support level, and at 10.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.77, and for the 2nd resistance point, it is at 10.97.
Ratios To Look Out For
For context, CorMedix Inc’s Current Ratio is 1.94. On the other hand, the Quick Ratio is 1.73, and the Cash Ratio is 0.36. Considering the valuation of this stock, the price to sales ratio is 3.88, the price to book ratio is 2.21 and price to earnings (TTM) ratio is 5.14.
Transactions by insiders
Recent insider trading involved Dillione Janet, Director, that happened on Dec 02 ’25 when 46657.0 shares were sold. Director, Dillione Janet completed a deal on Nov 24 ’25 to sell 26343.0 shares. Meanwhile, Director Janet Dillione bought 73000.0 shares on Nov 24 ’25.
